GAS5 and metastatic malignant neoplasm in the lymph nodes: Pooled data results (Table 3) showed that low GAS5 expression was significantly correlated with lymph node metastasis (OR = 1.92, 95% CI: 1.44–2.57, P < 0.001), distant metastasis (OR = 2.7, 95% CI: 1.05–6.97, P = 0.040), poor differentiation (OR = 1.98, 95% CI: 1.40–2.80, P < 0.001), larger tumor size (OR = 3.21, 95% CI: 2.08–4.95, P < 0.001), and advanced clinical stage (OR = 0.26, 95% CI: 0.18–0.38, P < 0.001).